Contents
Download PDF
pdf Download XML
47 Views
3 Downloads
Share this article
Research Article | Volume 14 Issue 5 (Sept - Oct, 2024) | Pages 653 - 660
A cross-sectional study on clinical, biochemical and angiographic parameters of coronary no reflows in patients undergoing primary percutaneous coronary intervention
 ,
 ,
1
Assistant Professor, Department of General Medicine, North Bengal Medical College and Hospital, Siliguri, West Bengal, India
2
Senior Resident, Department of General Medicine, North Bengal Medical College and Hospital, Siliguri, West Bengal, India
Under a Creative Commons license
Open Access
Received
Aug. 31, 2024
Revised
Sept. 10, 2024
Accepted
Sept. 25, 2024
Published
Oct. 26, 2024
Abstract

Background: Cardiovascular diseases (CVD) are one of the leading causes of mortality and morbidity worldwide. Among them the spectrum of ischemic heart disease which encompass stable ischemic heart disease, unstable angina, NSTEMI & STEMI is the commonest cause. Coronary no-reflow is a frequent phenomenon that develops in patients with ST-segment elevation myocardial infarction during reperfusion therapy. In this study, we focused on to assess the prevalence of coronary no reflow in STEMI patients undergoing primary PCI. Methodology: This study was conducted in patients in Cath lab, Coronary Care Unit and different wards of the department of Cardiology in Apollo Multispecialty Hospital Limited during the period of 18 months spanning from November 2021 to April 2023. Consecutive patients of STEMI who had undergone PPCI were enrolled in this study. The patients to be included are those with STEMI above age≥18 years. They were divided into no reflow and normal flow and their characteristics were studied. Results: The prevalence of no reflow was 9.93%. Majority of the patients had age more than 60 years (55%) whereas 45% of the patients were younger than 60 years with males (71%) and females (29%). Common associated condition with patients undergoing percutaneous coronary intervention in present study was hypertension (86%), dyslipidemia (80%) and diabetes mellitus (93%). TIMI thrombus scale and Myocardial blush grade (MBG) was significantly higher in patients with hypertension. There was a significant difference found in TIMI thrombus scale and MBG between diabetic and non-diabetic patients. There were significant differences found in mean LVEF in respect to myocardial blush grade (MBG). Conclusion: The TIMI thrombus scale and myocardial blush grade was found to be higher in patients with no reflow undergoing PCI. The prevalence of no reflow after primary PCI is 9.93%. The co morbidities like DM, hypertension and dyslipidemia were more common among these patients.

Keywords
INTRODUCTION

Cardiovascular diseases (CVD) are one of the leading causes of mortality and morbidity worldwide. [1] Among them the spectrum of ischemic heart disease which encompass stable ischemic heart disease, unstable angina, NSTEMI & STEMI is the commonest cause. Data from the Framingham Heart Study suggests lifetime risk for ischemic heart diseases among individuals is 37.5% for men and 18.3% in women and the incidence is on the ascendance. [2] The proportion of acute coronary syndrome cases which constitute STEMI varies across observational studies but the ratio has decreased in last decade due to increase in incidence of NSTEMI cases due to more sensitive and diligent detection methods. Reperfusion therapy within the recommended window period by Primary percutaneous coronary intervention (PPCI) is the gold standard of treatment of STEMI. PPCI restores thrombolysis in myocardial infarction (TIMI) 3 flow in over 90% of patients.[3] However there remains a small proportion of patients, who continue to exhibit overt impairment of myocardial perfusion despite successful opening of infarct related epicardial artery (IRA). This phenomenon is called no reflow or no flow, which refers to a state of myocardial hypoperfusion in the presence of patent epicardial coronary artery. Sudden loss of epicardial flow following balloon dilatation or stenting may also occur in incomplete lesion dilation, epicardial vascular spasm, epicardial dissection or in situ thrombosis. These procedural failures are totally different clinical subsets and need careful exclusion from no reflow which is mainly due to microvascular obstruction. Its overall incidence is 2% and in STEMI the incidence is 11-41%. [4] No reflow has a negative effect on the clinical outcome negating the potential benefit of PPCI in STEMI.[5,6,7] Indeed no reflow is regarded as an independent predictor of procedure related mortality and morbidity.[8] No reflow may set in a sudden and dramatic fashion after completion of PCI (within 1–2 h). Recognition of no reflow in the cath lab or coronary care unit is essential for salvaging the patient. [9]

 

Defined by angiography, the no-reflow phenomenon is manifested by an acute reduction in the coronary flow (thrombolysis in myocardial infarction [TIMI] flow grade=0–1) in the absence of dissection, thrombus, spasm, or high-grade residual stenosis at the original lesion site. Lesser degrees of flow impairment (TIMI score=2) are generally referred to as “slow flow”. Clinically no reflow may present with the recurrence of chest pain, cardiogenic shock with hypotension, malignant arrhythmias or acute dyspnea due to pulmonary edema secondary to heart failure. No reflow is a progressive phenomenon and its presentation may be delayed. Early detection, preventive measures and treatment of no reflow is imperative for a better outcome but often is unsatisfactory. It is crucial to identify which patients are more prone to develop no reflow. As for patient related factors previous studies found that advanced age, diabetes and hypertension are important predictors of no-reflow. Among biochemical parameters elevated White blood cell (WBC) count, thrombus grade/score, mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio, duration between onset of chest pain and PCI (≥4 h), hyperglycemia and raised serum creatinine were some predictors.[10,11] Coronary angiography is the conventional method to diagnose no reflow in the cath lab. No reflow is quantified by various scales like thrombolysis in myocardial infarction (TIMI) flow, corrected TIMI frame count (CTFC), TIMI myocardial perfusion grade (TMPG) and myocardial blush grade (MBG).[12,13] However, in practice, TIMI flow  and MBG are most commonly used. The clinical and biochemical parameters differ in patients with normal flow and those with no reflow which is investigated here. Also from the available literature there has been no study in Eastern India on this subject. Hence, present study was performed to investigate the clinical, laboratory and procedural characteristics associated with the no-reflow phenomenon in patients undergoing PPCI on native coronary arteries for STEMI.

 

Objectives:

To assess the prevalence of coronary no reflow in STEMI patients undergoing primary PCI and to assess the risk factors for such.

METHOD

This study was conducted in Coronary Care Unit and different wards of the department of Cardiology in Apollo Multispeciality Hospital Limited from November 2021 to April 2023. Consecutive patients of STEMI in the time frame who had undergone primary percutaneous coronary intervention were selected. Primary PCI was done and they were segregated into normal flow and no reflow groups based on TIMI flow grades.

 

Surface ECG was done for all patients at the emergency room or within 10 minutes after admission. Coronary angiography was performed and those fulfilling the criteria for intervention were recruited for the study. Contraindications like patients who need CABG or didn’t give consent were excluded. PCI was performed using a standard femoral or radial approach with a 6- or 7-F guiding catheter. All the patients receive 300 mg of oral aspirin and 600 mg of Clopidogrel or 180 mg of Ticagrelor immediately after admission. Patients who had high thrombus burden received GpIIbIIIa inhibitor infusion.

 

Data collection procedure: 

The patients of STE-ACS who fulfill the inclusion criteria were recruited by purposive conventional sampling in the stipulated study period. The patients who develop coronary no reflow were recruited and data were collected from all patients. Those who have any one or more of the exclusion criteria were excluded from the final sample size. For all these patients undergoing primary PCI history were noted and physical examination was done. Patients were taken to the operation theatre and during primary PCI different angiographic features documented during coronary angiography were noted. Biochemical and hematological parameters were noted from investigations done at time of admission.

 

The Statistical Package for the Social Sciences for Windows version 20 (IBM SPSS Inc., Chicago, IL, USA) were used for the statistical analysis. Normally distributed continuous data is described as mean±standard deviation, while non-normally distributed data is shown as median (range). Categorical variables are shown as number and percentage. For continuous variables, Student’s t test or the Mann Whitney U-test was used. To detect association between categorical variables, the chi-square test was used and Fisher’s exact test in the case of sparse data whenever appropriate.

RESULT

15x100

= 9.93

151

A total of 151 patients of STEMI were analyzed. Among them 15 patients had no reflow during PCI and 136 patients had normal flow.

So the prevalence of no reflow is

 

The different clinical, biochemical and angiographic parameters were noted and compared between the groups of patients.

 

Table 1: Comparison between mean ages of study participants

 

Group

P value

No reflow

Normal

Total

Mean

66.60

60.06

60.71

0.064

SD

14.242

12.762

13.014

 

Table 2: Comparison of sex distribution between groups

 

Group

Total

P Value

No reflow

Normal

Sex

Female

5

42

47

0.846

Male

10

94

104

 

Total

15

136

151

 

 

Table 3: Comparison of co morbidities between the two groups

 

Group

Total

P value

No Reflow

Normal

Diabetes mellitus

NO

1

50

51

0.019

YES

14

86

100

Hypertension

NO

2

85

87

<0.001

YES

13

51

64

Dyslipidemia

NO

3

45

48

0.302

YES

12

91

103

Hypothyroid

 

NO

8

81

89

0.642

YES

7

55

62

Peripheral vascular disease

NO

8

110

118

0.214

YES

7

26

33

Ischemic heart disease

NO

11

101

112

0.924

YES

4

35

39

Family history of coronary artery disease

NO

9

95

104

0.676

YES

6

41

47

 

Table 4: Comparing addiction habits between groups

 

Group

Total

P value

No reflow

Normal

Smoking

NO

9

72

81

0.838

YES

6

64

70

Alcohol

NO

10

80

90

0.557

YES

5

56

61

 

Table 5: Association between BMI and TIMI flow

 

TIMI flow

Total

P value

1

2

3

BMI

Underweight

0

2

0

2

0.022

Normal

4

6

34

44

Overweight

4

4

56

64

Obese

4

4

27

35

Severe obese

0

0

5

5

Morbid obese

0

1

0

1

Total

12

17

122

151

 

 

Table 6: Correlation between biochemical parameters and flow

Biochemical parameters

Group

P value

No reflow

Normal Flow

H/R

64.13±14.81

69.56±15.77

0.206

SBP

105.33±16.41

109.89±16.22

0.304

DBP

61.33±8.64

62.98±10.75

0.568

Hemoglobin

11.460±2.32

12.05±2.03

0.298

WBC

12800.0±3833.87

9033.24±2392.44

<0.001

Neutrophils

88.67±2.74

75.75±7.39

<0.001

Lymphocyte

7.73±2.57

17.68±6.77

<0.001

Platelet

4.16±1.58

1.75±0.59

<0.001

PCV

34.53±7.57

36.95±6.29

0.169

Urea

76.13±27.55

41.57±24.63

<0.001

Creatinine

2.22±0.68

1.36±0.47

<0.001

RBS

299.60±79.48

218.29±72.0

<0.001

CPK

200.73±40.03

169.59±34.92

0.002

CPK-MB

48.40±12.37

34.79±13.64

<0.001

cholesterol

213.80±43.93

192.03±35.54

0.030

TG

134.80±23.39

126.09±24.16

0.186

HDL

39.20±6.27

42.94±5.55

0.016

LDL

123.53±25.17

107.96±25.93

0.028

 

Table 7: Correlation between biochemical parameters and TIMI flow

Biochemical parameters

TIMI flow grade

P value

1

2

3

Mean

SD

Mean

SD

Mean

SD

H/R

64.33

15.808

79.82

12.953

67.98

15.549

0.007

SBP

107.33

17.084

111.53

14.449

109.35

16.494

0.786

DBP

62.75

8.170

62.76

9.404

62.83

10.966

0.999

Haemoglobin

11.508

2.3750

12.324

2.1727

11.988

2.0224

0.580

WBC

13458.33

3888.084

8747.06

2502.778

9100.98

2384.314

<0.001

Neutrophils

88.25

2.864

77.47

10.578

75.87

7.152

<0.001

Lymphocyte

8.17

2.691

15.94

9.270

17.63

6.548

<0.001

Platelet

4.4908

1.39188

1.7194

1.00338

1.7780

.58754

<0.001

PCV

34.75

7.887

37.65

6.670

36.77

6.285

0.480

Urea

78.50

30.183

56.29

51.700

40.13

17.571

<0.001

Creatinine

2.2333

.62426

1.5647

.95325

1.3502

.39676

<0.001

RBS

279.83

67.371

249.71

100.706

217.85

71.186

0.011

CPK

203.83

44.452

169.53

30.038

170.06

35.370

0.008

CPK-MB

51.25

11.841

34.76

7.387

34.84

14.211

<0.001

Cholesterol

219.50

46.349

190.24

34.572

192.25

35.582

0.045

TG

135.50

24.858

126.82

22.498

126.13

24.335

0.442

HDL

38.75

6.580

44.65

5.733

42.66

5.495

0.021

LDL

124.17

28.025

108.24

22.852

108.24

26.214

0.130

 

Table 8: Comparing localization between groups

 

Group

Total

P value

No reflow

Normal

Localization

Anteroseptal

2

19

21

0.308

Anteroapical

0

20

20

Anterolateral

3

17

20

Extensive anterior

2

10

12

Lateral

0

1

1

Posterolateral

0

6

6

Infero lateral

3

7

10

Inferior

4

27

31

Posteroinferior

1

22

23

Anteroinferior

0

7

7

Total

15

136

151

 

 

 

DISCUSSION

In our study the prevalence of no reflow was 9.93%. This was slightly lower than the previous data. One potential explanation for this difference might be the application of a standardized definition of no-reflow such as angiographically visible flow impairment despite patent epicardial coronary arteries whereas other studies have taken liberal definitions such as failure to achieve TIMI 3 flow at the conclusion of the procedure or usage of more sensitive tests like perfusion imaging. Usage of glycoprotein IIbIIa inhibitors was quite frequent compared to other studies resulting in lower incidence.[39] In our study, majority of the patients had age more than 60 years (55%) whereas the patients with no reflow had a mean age of 66 years compared to 60 years in normal flow. Explanation for this is probably due to pre-existing microvascular dysfunction. There was male preponderance both in patients with STEMI about 69% and in those with no reflow about 66%. This is similar to the  study conducted by Refaat et al.[15] who found that the mean age of the no-reflow group was significantly higher than that of the normal flow one (65.21 ± 11.89 vs. 56.61 ± 10.39 years, P < 0.001) with similar proportion of male female proportion. We reported that the majority of the patients of ACS in present study belonged to upper middle class 42%. Among patients of no reflow 26.7% belonged to upper, upper middle and upper lower class category. We reported the most common associated condition with patients of no reflow while undergoing percutaneous coronary intervention in present study was diabetes mellitus (93%), hypertension (86%), dyslipidemia (80%) with lesser prevalence of hypothyroidism (46%), IHD (26%) , family history of CAD (40%), peripheral vascular disease (46%). Among these factors diabetes and hypertension was significantly higher compared to patients with normal flow. Recent studies have suggested that no reflow is more commonly seen in combination with hyperglycemia, hypercholesterolemia, and mild to moderate renal insufficiency. [16]

 

In our study, out of 151 patients, 46% of patients were smokers whereas 40% indulged in consumption of alcohol. There was no statistical significance among these habits between the two groups. Confounding factor in our study is women are usually teetotalers conforming to Indian society norms so smoking pattern has appeared non-significant. This is further substantiated by the fact; among the 6 smokers who had no reflow 5 were male and a solitary female. In a recent study from Thailand among 22741 subjects no reflow and also long term MACE was more among smokers after adjustment for baseline characteristics. The pathogenesis for smoking related cardiovascular disorders is multifactorial involving inflammation, plaque rupture, augmented thrombotic factors, hepatic enzyme induction, and drug interaction and medication compliance.[17] We reported that the majority of the patients undergoing PCI were overweight (42%). We found a significant association between BMI and TIMI flow (p<0.05) showing that patients with higher BMI had poor flow. This was similar to the results found by Hawkins et al.[18] that the slow flow patients were significantly more obese (BMI 33.9 vs. 29.8 kg/m2, P=0.003) and had significantly lower levels of high-density lipoprotein (HDL) compared with normal flow patients (39.7 vs. 45.7mg/dl, P= 0.04). Kosugeet al. [19] found that there was a trend toward a lower TIMI flow grade with increasing BMI. This may be partly due to alterations in hemostatic variables, associated with hypercoagulable states like plasminogen activator inhibitor. In our study 33% of patients presented in the time frame of 24-48 hours. The time window for reperfusion therapy in STEMI is based on current understanding and evidence of the benefits of reperfusion therapy. As  more clinical evidences have showed up, the reperfusion time window for STEMI patients has been expanded from 12 hours to 48 hours.[20] In the recent Polish Registry of Acute Coronary Syndrome (PL-ACS) outcome of reperfusion in late presenters was evaluated at 12 months where there was lower mortality in the invasive arm substantially. Bouisset et al [21] analyzed observational studies enrolled in the monthly FAST-MI program and revascularized patients did well at a median follow up of 58 months. No reflow is a common complication among late presenters but there is no causal association. There was no significant difference found in conventional TIMI flow grade between the two groups with previous use of antiplatelet, dyslipidemic drugs, anti-anginal, ACEIs and diuretics drugs as revealed by insignificant p value of >0.05. The RAS axis activation results in increased production of angiotensin II which subsequently increases vascular resistance, myocardial workload, and myocardial oxygen demand. In our study use of the medicines didn’t have statistically significant effect among the groups because most of the patients were already on these medicines for other indications like hypertension & diabetic nephropathy. But the incidence of no reflow was lower than current data among all the ACS patients. Our study found that inferior wall MI was most common among patients with no reflow but there was no statistical difference. In CREATE registry, 60.6% presented with STEMI, whereas in Kerala ACS registry[22] 37% of total patients with ACS presented with STEMI and in Global Registry of Acute Coronary Events (GRACE) study, STEMI cases ranged between 30 and 40%.[23] There were significant differences in mean LVEF in respect to conventional myocardial blush grade (MBG) as lower LVEF was seen in lower grades. MBG reflects myocardial perfusion and microvascular patency so, it has been termed as an independent predictor of residual ejection fraction >50%, in patients with STEMI. Lower LVEF implies higher chance of heart failure which is one of the effects of no reflow. In addition, the MBG may reflect the patency of the microvasculature and has been found to have an additive predictive value for long term mortality and infarct size after PPCI.[24] TIMI thrombus scale was higher in the no reflow group. There was no significant association with use of GpIIbIIa inhibitors between the two groups.

CONCLUSION

In conclusion, we found that elderly male patients with higher BMI were more associated with no reflow. The comorbidities like DM, hypertension and dyslipidemia were more common among these patients. We found that TLC, neutrophil, serum urea and creatinine level, CRP and CPK-MB level showed significance regarding the prediction of no reflow. Majority of the patients had the site of ischemia located to the inferior wall followed by antero-apical wall. Delay in time of presentation, higher grade of thrombus are some other predictive factors. The TIMI thrombus scale and myocardial blush grade was found to be higher in patients with no reflow undergoing PCI.

 

Conflict of interest: None declared

 

Funding: Nil

REFERENCES
  1. Okwuosa IS, Lewsey SC, Adesiyun T, et al. Worldwide disparities in cardiovascular disease: challenges and solutions. Int J Cardiol 2016; 202:433–40.
  2. Braunwald’s Heart disease; a textbook of cardiovascular medicine, 11th edition
  3. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016 Jul-Aug; 68(4):539-51.
  4. Harrison R.W., Aggarwal A., Ou F.S. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013; 111(2):178–184
  5. Jaffe R., Dick A., Strauss B.H. Prevention and treatment of microvascular-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. J Am CollCardiolInterv. 2010; 3:695–704.
  6. Eeckhout E., Kern M.J. Clinical perspective: the coronary no-reflow phenomena: a review of mechanisms and therapies. Eur Heart J. 2001; 22:729–739.
  7. Brosh D., Assali A.R., Mager A. Effect of no reflow during primary percutaneous coronary intervention for acute myocardial infarction on six month mortality. AmJCardiol. 2007; 99:442–445.
  8. Ndreppa G., Tiroch K., Keta D. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. CircCardiovascInterv. 2010;3:27–33.
  9. Berg R., Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. CurrCardiol Rev. 2012;8:209–214.
  10. Danesh Sani H.D., Eshraghi A., Sahri B., Vejdanparast M. No-reflow phenomenon in patients with ST-elevation acute myocardial infarction, treated with primary percutaneous coronary intervention: a study of predictive factors. J Cardiothorac Med. 2014;2(4):221–226.
  11. Abdi S., Rafizadeh O., Peighambari M., Basiri H., Bakhshandeh H. Evaluation of clinical and procedural predictive factors of no-reflow phenomenon following primary percutaneous coronary intervention. Res Cardiovasc Med. 2005;4(2):e25414.
  12. Gibson M.C., Cannon C.P., Murphy S.A., Marble S.J., Barron H.V., Braunwald E. Relationship of TIMI myocardial perfusion grades, flow grades, frame count and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–1913.
  13. Hoffmann P., Haager P., Lepper W., Franke A., Hanrath P. Relation of coronary flow pattern to myocardial blush grade in patients with first myocardial infarction. Heart. 2003;89(10):1147–1151.
  14. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS. Incidence and treatment of “no-reflow” after percutaneous coronary intervention. Circulation 1994;89:2514e2518.
  15. Refaat H, AymanTantawy, Amr S. Gamal, HananRadwan. Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Indian Heart Journal. Volume 73, Issue 1,2021, Pages 35-43
  16. Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, Keskin M, et al. CHA2DS2- VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology. 2016 Oct;67(9):840-5.
  17. Sabin P, Koshy AG, Gupta PN, Sanjai PV, Sivaprasad K, Velappan P, Vellikat Velayudhan R. Predictors of no- reflow during primary angioplasty for acute myocardial infarction, from Medical College Hospital, Trivandrum. Indian Heart J. 2017 Apr;69Suppl 1(Suppl 1):S34-S45. doi: 10.1016/j.ihj.2016.12.012. Epub 2017 Jan 6. PMID: 28400037; PMCID: PMC5388018.
  18. Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary Slow Flow–Prevalence and Clinical Correlations–. Circ J. 2012;76(4):936–42.
  19. Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Impact of body mass index on in-hospital outcomes after percutaneous coronary intervention for ST segment elevation acute myocardial infarction. Circ J. 2007;72(4):521–5.
  20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.
  21. Frédéric Bouissetet al.  Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI: J Am Coll Cardiol 2021 Sep 28;78(13):1291-1305. DOI: 10.1016/j.jacc.2021.07.039. PMID: 34556314
  22. Mohanan PP, Mathew R, Harikrishnan S, Krishnan MN, Zachariah G, Joseph J, et al. Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur Heart J. 2013;34(2):121–9.
  23. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson F, GRACE and GRACE2 Investigators. The global registry of acute coronary events, 1999 to 2009–GRACE. Heart. 2010;96(14):1095–101.
  24. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001;104(6):636–41.
Recommended Articles
Research Article
An Observational Comparative Study of Hematological, Inflammatory Biochemical and Radiological Abnormalities Between Survived and Non-Survived Patients Affected with Sars-Cov- 2 Pneumonia
...
Published: 14/10/2024
Download PDF
Research Article
Analyzing and contrasting of oxidative stress and antioxidant status in ischemic and hemorrhagic cases of stroke
Published: 26/12/2023
Download PDF
Research Article
The Incidence of Suboptimal Stenting and Complications in Severe Calcific Coronaries Undergoing Intra-Vascular Lithotripsy
...
Published: 31/10/2024
Download PDF
Research Article
A Comparative Study of The Efficacy of Ondansetron, Dexamethasone, And Ondansetron-Dexamethasone Combination for Postoperative Nausea and Vomiting Prophylaxis in Patients Undergoing Laparoscopic Surgeries
...
Published: 08/11/2024
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.